Logo

Sanofi Reports Results of Zynquista (sotagliflozin) in P-III InSynchrony Program for Type2 Diabetes and Terminates Its Collaboration with Lexicon

Share this

Sanofi Reports Results of Zynquista (sotagliflozin) in P-III InSynchrony Program for Type2 Diabetes and Terminates Its Collaboration with Lexicon

Shots:

  • The three P-III studies (SOTA-MET- SOTA-CKD3- SOTA-CKD4) involves assessing of Zynquista vs PBO in patients with T2D. The first two studies resulted in meeting its 1EPs i.e- @26wks. reduction in HbA1c while SOTA-CKD4 did not demonstrate a reduction in HbA1c
  • Additionally- Sanofi to terminates its development and commercialization agreement with Lexicon for Zynquista in all ongoing global studies for T1D & T2D signed in Nov’2015 following the results of P-III InSynchrony program
  • Zynquista is an oral SGLT1 and SGLT2 inhibitor which are responsible for glucose absorption in GI tract & kidney respectively and has received approval as an adjunct to insulin therapy to improve glycemic control in patients with T1D Mellitus with BMI ≥ 27 kg/m2 in the EU

Click here to­ read full press release/ article | Ref: Sanofi | Image: Wsj


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions